Test Procedure : 1,25 dihydroxy-vitamin D

Test Procedure   :  1,25 dihydroxy-vitamin D   : 

Why Get Tested?

To determine the  vitamin D deficiency; to determine the appropriate vitamin D supplementation level.

When to Get Tested?

If you have an abnormal calcium, phosphorus, and/or parathyroid hormone level, if you have evidence of diseases related to bones.Doctors may suggest vitamin D in case of you might have vitamin D deficiency or before  going to start a drug treatment for osteoporosis.

 Sample Required?

Blood sample required for this test procedures , which will be collected from the vein

Withdraw multiple drugs sold under same name: DCGI

The India drug regulator has asked pharmaceutical firms to withdraw several medicines sold under the same brand name but used to treat different ailments as it leads to confusion and could harm consumers for taking a wrong medicine.
On Monday, the Drug Controller General of India (DCGI), Surinder Singh, asked all state drug regulators to immediately withdraw three separate medicines used as an anti-allergic, antibiotic and anti-parasitic all sold under the brand AZ by three local drugmakers-Sienna Formulations, Cure Quick Pharma and Eugenics . He also asked the state authorities to get pharma companies to recall all such medicines sold under the same brand before relaunching under different names.
Experts estimate there may be about 100 such medicines that may be affected from the decision but the authorities will not be able to effectively enforce the same in the absence of a centralised drug brands database. "How will a drug regulator in Kolkata know which brand his Tamil Nadu counterpart has approved and is marketed in that state?" CMD Gulati, drug regulatory expert and editor of the medical journal Monthly Index of Medical Specialties, said. State drug regulators should maintain a database of brands and aggregate it at the central level, he said. The problem arises from fact that drug marketing licences are given by the DCGI after efficacy and safety of a medicine is established. The manufacturing licences are then awarded by respective state drug regulators where the companies are based.
Companies submit details of the chemical and the drug brands only at the time of application at the state drug regulator for manufacturing license.

IPC, USP to conduct joint workshop in Hyderabad on February 17 & 18IPC, USP to conduct joint workshop in Hyderabad on February 17 & 18

Indian Pharmacopoeia Commission (IPC) and the United States Pharmacopoeia (USP) are jointly conducting a two-day workshop in Hyderabad from February 17 to 18. The workshop will focus on strengthening the relation between the two standards setting authorities so as to address common challenges and possibilities to resolve them, but mainly it aims at gaining mutual recognition.

Dr G N Singh, secretary cum scientific director, IPC informed that the collaboration aims at focusing on the Indian requirements of Indian Pharmacopoeia (IP) and also to send in the message across the world that the IP has its own credibility and it should be accepted across the world as a book of standard of Indian drug.

He stressed, "Our objective is to emphasise that now it is time to accept the IP as the book of standard. We except USP which the book of standard of the US in India as it is and thus it will only be natural for the US authorities to accept the IP as the book of standard in their country as well for the Indian drugs."

The workshop is part of an ongoing process between both the standard setting authorities that focuses on assuring the quality of medicines as a priority for public health need. Events like this is aimed at improving the performance of IP through harmonisation of procedures and data sharing etc.

The Indian Pharmacopoeia (IP) is the legally recognised book of standards for monitoring the quality of drugs and pharmaceuticals as per the Drugs and Cosmetics Act, 1940 at regular and shorter intervals. Recently the 6th edition of Indian Pharmacopoeia has been prepared by the Commission in accordance with the principles and designed plan decided by its Scientific Body and completed through the untiring efforts of its members and Secretariat over a period of about two years.

Drugs approved Today by FDA

CAPECITABINE    :    Info about this product


ORLISTAT             :   Info about this product